This study explores the impact of a Medicare Part D formulary tier change, specifically with respect to branded insulin products, on insulin adherence, hemoglobin A1C, and diabetes-related events in elderly diabetic beneficiaries strategies for selection of appropriate and cost-effective therapy will also be discussed.
